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The penetration of trovafloxacin into human polymorphonuclear leukocytes (PMNs), human peritoneal
macrophages, and tissue-cultured epithelial cells (McCoy cells) was evaluated. The cellular concentration to
extracellular concentration (C/E) ratios of trovafloxacin were greater than 9 for extracellular concentrations
ranging from 0.5 to 25 mg/ml. The uptake of trovafloxacin by PMNs was rapid, reversible, nonsaturable, not
energy dependent, and significantly increased at pH 6. The C/E ratios of trovafloxacin were not affected by cell
viability but were significantly increased at 4&C. Ingestion of opsonized zymosan, but not opsonized Staphylo-
coccus aureus, significantly increased the amount of PMN-associated trovafloxacin. This agent at concentra-
tions of 0.5 and 1 mg/ml induced a greater reduction in the survival of intracellular S. aureus in PMNs than
ciprofloxacin and ofloxacin. It was concluded that trovafloxacin reaches concentrations within phagocytic and
nonphagocytic cells several times higher than the extracellular ones, while it remains active in PMNs.
Most fluoroquinolones are able to concentrate in phagocytic
and nonphagocytic cells, reaching concentrations several times
higher than the extracellular ones (9). Moreover, these agents
have been shown to remain active intracellularly against dif-
ferent facultative intracellular pathogens.
Most studies on the intracellular pharmacology of antimi-
crobial agents have used human phagocytes, and only a few
studies have evaluated the penetration into other types of cells.
Nevertheless, the pathogenic mechanism of several infections
involves the survival of bacteria in nonphagocytic cells, as has
been described for Chlamydia trachomatis and enteroinvasive
Escherichia coli in epithelial cells.
An important limitation of most commercially available
fluoroquinolones is their limited activity against gram-positive
pathogens. In recent years, however, new quinolones that offer
good activity against these bacteria have been described.
Among them, sparfloxacin has been shown to penetrate rapidly
into phagocytic cells, remaining active against Staphylococcus
aureus (4).
Trovafloxacin (CP-99,219) is a new azabicyclo naphthyri-
done agent with a broad spectrum of antibacterial activity
which includes gram-positive bacteria such as Streptococcus
pneumoniae and S. aureus (6). Moreover, this agent showed
high in vitro activity against Chlamydia trachomatis (2).
The purpose of this study was to evaluate the uptake of
trovafloxacin by human polymorphonuclear leukocytes (PMNs),
human peritoneal macrophages (PMfs), and tissue-cultured
epithelial cells. The mechanism involved in the penetration of
this agent into human PMNs and its intracellular activity com-
pared with those of ciprofloxacin and ofloxacin were also eval-
uated.
MATERIALS AND METHODS
Isolation of phagocytes. PMNs were recovered from the heparinized venous
blood of healthy donors and were purified by previously described methods (10).
PMN preparations were .97% pure. PMfs were isolated from peritoneal efflu-
ents of patients undergoing continuous ambulatory peritoneal dialysis (CAPD)
and who were being followed up by the Nephrology Department of the Univer-
sity Hospital of Seville, as described previously (13). Donors were clinically
uninfected at the time of the study. Cell preparations from the CAPD donor
always contained .75% PMfs and ,15% PMNs. Final cell suspensions were
adjusted to 2 3 106 PMfs/ml or 2 3 106 PMNs/ml in Hanks balanced salt
solution (HBSS) containing 0.1% gelatin. Both populations of cells were $95%
viable by trypan blue exclusion criteria.
Tissue culture cells. McCoy cells (Flow Laboratories, Irvine, United King-
dom) were grown in minimal essential medium (Flow) supplemented with 1 mM
HEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; Flow) and con-
taining 10% fetal calf serum (Flow) without antibiotics. For each experiment, the
cells were detached from the tissue culture bottles with trypsin-EDTA (Flow),
washed once with minimal essential medium containing fetal calf serum (10%),
and suspended in HBSS at a concentration of 5 3 106 cells per ml.
Trovafloxacin uptake by cells. Uptake of radiolabeled trovafloxacin by phago-
cytic and epithelial cells was determined by a velocity gradient centrifugation
technique described by Klempner and Styrt (7). [14C]trovafloxacin (21.53 mCi/
mg) and trovafloxacin were kindly supplied by Pfizer Central Research (Groton,
Conn.). In these experiments, phagocytes or tissue cells were incubated in HBSS
containing different concentrations of trovafloxacin (0.5, 1, 2, 5, 10, and 25
mg/ml). After different incubation periods at 378C, the cells were separated from
the extracellular solution by centrifugation through a water-impermeable silicone
oil barrier in a microcentrifuge tube. A 10-ml aliquot of the extracellular medium
and the entire cell pellet, obtained by cutting off the portion of the microcentri-
fuge tube containing the pellet, were placed in 3 ml of scintillation fluid (Ready
Micro; Beckman Instruments, Inc., Fullerton, Calif.), and the radioactivity was
counted in a liquid scintillation counter (model LS 1801; Beckman). After de-
termination of the cell volume with radiolabeled polyethylene glycol and water
(New England Nuclear), the rate of accumulation of the antimicrobial agent in
PMNs, PMfs, or tissue cells was calculated and expressed as cellular concen-
tration to extracellular concentration (C/E) ratio (13).
Characterization of trovafloxacin uptake. Further studies to elucidate the
mechanism of trovafloxacin uptake by PMNs were performed as described pre-
viously (10). The importance of cell viability was studied by using PMNs killed by
exposure to 10% formalin for 30 min. These cells were then washed and sus-
pended in fresh medium. Moreover, the influence of environmental temperature,
pH, and metabolic inhibitors was evaluated. The influence of temperature was
examined by comparing antimicrobial uptake at 4 and 378C. The pH profiles of
trovafloxacin uptake in media preadjusted to different external pHs (pH 6, 7, and
8) by the addition of 10 N HCl or 10 N NaOH were measured. An inhibitor of
glycolysis (sodium fluoride, 1.5 3 1023 M; Sigma Chemical Co., St. Louis, Mo.),
an inhibitor of mitochondrial oxidative metabolism (sodium cyanide; 1.5 3 1023
M; Sigma), a blocker of the proton gradient (carbonyl cyanide m-chlorophenyl-
hydrazone; 1.5 3 1025 M; Sigma), and an uncoupler of oxidative phosphoryla-
tion (2,4-dinitrophenol; 1 3 1024 M; Sigma) were used as metabolic inhibitors.
PMNs in HBSS with and without metabolic inhibitors were incubated for 30 min
at 378C, trovafloxacin (final concentration, 2 mg/ml) was then added, and the
uptake was measured, as described above.
In a series of experiments, trovafloxacin (extracellular concentration, 2 mg/ml)
uptake by human PMNs was measured after the stimulation of cells with 200 nM
phorbol myristate acetate (PMA; Sigma) and after the phagocytosis of either
opsonized zymosan (0.9 mg/liter; Sigma) or S. aureus ATCC 25923, opsonized in
5% pooled human serum (15 min at 378C) at a 10/1 ratio of bacteria to PMNs.
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PMA or opsonized particles were added to PMN suspensions at the same time
that the antimicrobial agent was added, and the uptake was measured as de-
scribed above.
The efflux or reversibility of the binding of cell-associated trovafloxacin was
also studied. PMNs, PMfs, or McCoy cells were incubated for 10 min at 378C
with trovafloxacin (extracellular concentration, 2 mg/ml), collected by centrifu-
gation, and rapidly suspended in quinolone-free medium. Cell-associated trova-
floxacin was quantified at various time intervals (5, 10, and 20 min) after the
removal of the extracellular antimicrobial agent. All assays were performed in
duplicate with PMNs from five different donors.
Partition coefficient of quinolones. The partition coefficients of quinolones
were determined by the modified method of Nikaido (8). Solutions (10 mg/ml) of
quinolones were made in 0.1 M phosphate buffer (pH 7.2). After being shaken
with an equal volume of n-octanol at 258C for 48 h and centrifuged at 1,870 3 g
for phase separation, the concentrations of quinolones in the aqueous phase
were determined by a spectrophotometric assay measuring the A260 for trova-
floxacin and the A286 for ofloxacin (Hoechst AG, Barcelona, Spain). The parti-
tion coefficients were expressed as the ratio of the amount of the compound in
the n-octanol to that in the aqueous phase.
Organisms and susceptibility testing. S. aureus ATCC 25923 was used for the
killing assays. Susceptibility studies were determined by dilution assay. The MICs
and minimum bactericidal (MBCs) of ciprofloxacin (Bayer AG, Leverkusen,
Germany), ofloxacin (Hoechst AG), concentrations and trovafloxacin for this
strain were 0.25, 0.25, and 0.03 mg/ml, respectively.
Intracellular activities of antimicrobial agents. To evaluate the intracellular
activities of antimicrobial agents, a previously described method was used (13).
Briefly, 0.1 ml of opsonized bacterial suspension (53 107 CFU/ml) and 0.1 ml of
PMNs (5 3 106 PMNs per ml) were combined in a series of polypropylene
biovials (Beckman), and the vials were incubated in a shaker (250 rpm) for 60
min at 378C. After incubation, the mixtures were washed three times with 2.5 ml
of ice-cold phosphate-buffered saline by using differential centrifugation (160 3
g; 5 min at 48C) to remove the extracellular bacteria. The cells were then
suspended in 0.2 ml of RPMI medium (Sigma). At this time, different concen-
trations of the different fluoroquinolones were added, and the vials were incu-
bated in a shaker (50 rpm) at 378C. The vials were removed at time zero and after
3 h of incubation (control and samples with antimicrobial agents). Cells were
lysed in distilled water, and samples were diluted and pour plated in agar.
Colonies were counted after 24 h of incubation at 378C. The data were expressed
as the percentages of staphylococci surviving compared with the levels in the
controls (without antimicrobial agents) at 3 h. In addition to determining bac-
terial survival, morphologic studies were also routinely performed at time zero
and after 3 h of incubation to evaluate the disposition of the bacteria (cell
associated or extracellular). Samples (50 ml) were removed from the biovials and
were deposited on glass slides. After being stained with Wright stain, the samples
were examined by light microscopy. All assays were performed in duplicate with
PMNs from five different donors.
Statistical analysis of data. The data were expressed as the means 6 standard
deviations. Differences among groups were compared by analysis of variance,
used to assess statistical significance at P # 0.05.
RESULTS
Uptake of trovafloxacin by PMNs, PMfs, and McCoy cells.
Figure 1 shows the kinetics of uptake of trovafloxacin by hu-
man PMNs. Trovafloxacin uptake by these cells was rapid and
high. With extracellular concentrations of 2 mg/ml, the C/E
ratios were greater than 10 after 1 min of incubation. The effect
of the extracellular concentrations of trovafloxacin on uptake
by PMNs is presented in Fig. 2. Cell-associated trovafloxacin
was not saturable at extracellular concentrations ranging from
0.5 to 25 mg/ml. The uptake of trovafloxacin by human PMfs
and tissue-cultured epithelial cells was similar to that obtained
with PMNs. At extracellular concentrations of 2 mg/ml (30 min;
378C), the C/E ratios were 10.6 6 2.0 for PMNs, 10.2 6 2.0 for
PMfs, and 9.6 6 1.9 for McCoy cells.
The effects of pH, environmental temperature, cell viability,
and metabolic inhibitors on the uptake of trovafloxacin by
human PMNs are indicated in Table 1. Trovafloxacin uptake
by PMNs was significantly higher at pH 6 and when viable
PMNs at 48C were used. None of the metabolic inhibitors used
affected the intracellular penetration of this quinolone.
The stimulation of PMNs by a membrane activator (PMA)
and the phagocytosis of opsonized S. aureus cells did not affect
the intracellular penetration of trovafloxacin (C/E ratios, 9.06
1.7 and 8.2 6 1.6, respectively). The phagocytosis of opsonized
zymosan, however, significantly increased the uptake of trova-
floxacin by PMNs (C/E ratio, 13.9 6 1.7; P , 0.05).
To evaluate whether trovafloxacin that had been taken up by
human PMNs, PMfs, and tissue-cultured epithelial cells was
tightly bound to cellular components, we evaluated the kinetics
of efflux (Fig. 3). The reversibility of binding of trovafloxacin
was rapid, with 80, 65, and 72% of the cell-associated drug
being lost by 5 min in PMNs, PMfs, and McCoy cells, respec-
tively. The kinetics of the efflux of trovafloxacin from PMNs at
378C was similar to that observed in PMNs at 48C or dead
PMNs at 378C (data not shown).
Partition coefficient of quinolones. The partition coefficients
of trovafloxacin and ofloxacin were 0.646 and 0.168, respec-
tively. This means that trovafloxacin is approximately four
times more hydrophobic than ofloxacin.
Intracellular activity of trovafloxacin. The intracellular ac-
tivity of trovafloxacin against S. aureus compared with those of
ciprofloxacin and ofloxacin was evaluated by a 3-h assay (Fig.
4). At extracellular concentrations of 0.5 and 1 mg/ml, the
intracellular activity of trovafloxacin was significantly greater
than those of ciprofloxacin and ofloxacin.
FIG. 1. Kinetics of trovafloxacin uptake by human PMNs (n 5 5). The
extracellular concentration was 2 mg/ml. Error bars indicate standard deviations.
FIG. 2. Trovafloxacin uptake by human PMNs at different extracellular con-
centrations (n 5 5). Incubations were carried out for 20 min. Error bars indicate
standard deviations.
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The uptake of radiolabeled trovafloxacin by phagocytic cells
(PMNs and PMfs) and nonphagocytic cells has been evalu-
ated. At therapeutic extracellular concentrations, trovafloxacin
reached concentrations in PMNs 10 or more times higher than
the extracellular concentrations. These values were slightly
higher than those observed with other fluoroquinolones such
as ofloxacin, lomefloxacin, sparfloxacin, and BAY-Y-3118 (4,
5, 11, 12). This could be related to the fact that trovafloxacin is
more hydrophobic than those quinolones and theoretically
could pass more easily through the cell membrane.
The uptake of trovafloxacin by PMfs was similar to that
observed for PMNs. This finding could be interesting since
intraleukocytic survival of bacteria has been postulated as an
important cause of persistent peritonitis in patients undergoing
CAPD (1) and little information on the penetration of antimi-
crobial agents in human PMfs is available. At higher extracel-
lular concentrations (10 mg/ml) and under different experimen-
tal conditions, Edelstein et al. (3) reported C/E ratios for
trovafloxacin of greater than 20 for guinea pig alveolar mac-
rophages.
Trovafloxacin also reached high intracellular concentrations
(C/E ratios,$9) in tissue-cultured epithelial cells. These values
are higher than those observed for ofloxacin and sparfloxacin
(4, 11). Since trovafloxacin yielded high intrinsic activity
against C. trachomatis and since these microorganisms multiply
within epithelial cells, these results could reinforce the poten-
tial use of this agent against chlamydial infections.
The uptake of trovafloxacin by human PMNs was rapid,
nonsaturable (extracellular concentrations ranged from 0.5 to
25 mg/ml), reversible (as was the case for PMfs and McCoy
cells), and not energy dependent. It was significantly increased
at acidic pH, as was reported elsewhere for other quinolones
(4, 5), but to a lesser extent. This phenomenon could be related
to the fact that such quinolones display a free carboxyl group
that becomes protonated when the pH changes from alkaline
to acidic. It has been observed that the ionized forms of weak
organic acids diffuse through biological membranes much
more slowly than their un-ionized forms (14). The uptake of
trovafloxacin by human PMNs was significantly increased at
48C and was not affected by cell viability. We have previously
observed that the uptake of some quinolones such as tema-
floxacin and lomefloxacin significantly decreased at 48C and
was affected by cell viability (12), while the uptake of other
quinolones such as sparfloxacin was not affected by these pa-
rameters (4). We have not previously observed such a remark-
able increase at 48C with other quinolones. These data could
indicate that more than one mechanism may mediate the in-
tracellular penetration of different quinolones. For trovafloxa-
cin, most data show that a passive mechanism, such as that
described for sparfloxacin (4), is involved.
The effects of phagocytosis and stimulation of the cell mem-
brane on the uptake of trovafloxacin by human PMNs was
similar to those previously observed with sparfloxacin (4). The
ingestion of opsonized S. aureus cells did not affect the intra-
cellular penetration of trovafloxacin, but the ingestion of op-
sonized zymosan significantly increased the C/E ratio for trova-
floxacin. Nevertheless, the uptake of trovafloxacin was still high
under both conditions.
At extracellular concentrations of 0.5 and 1 mg/ml, trova-
floxacin showed activity against S. aureus greater than those of
ciprofloxacin and ofloxacin in human PMNs. This effect was
partially due to a higher intrinsic activity of trovafloxacin
against the strain that we used.
In summary, trovafloxacin penetrates into phagocytic and
nonphagocytic cells, reaching intracellular concentrations sev-
eral times greater than the extracellular ones, while it remains
FIG. 3. Efflux of trovafloxacin from human PMNs, PMfs, and McCoy cells
(n 5 3). After incubation with 2 mg of trovafloxacin per ml for 20 min, the cells
were washed and resuspended in antimicrobial agent-free medium. Cell-associ-
ated trovafloxacin was then measured at different times.
FIG. 4. Activity of trovafloxacin compared to those of ciprofloxacin and
ofloxacin against intracellular S. aureus in human PMNs (n 5 5). Data are
expressed as percentages of surviving bacteria compared to that for the control.
Error bars indicate standard deviations. *, P , 0.05 compared to ciprofloxacin and
ofloxacin.
TABLE 1. Effects of pH, cell viability, environmental temperature,
and metabolic inhibitors on the intracellular penetration
of trovafloxacin in human PMNs
Conditiona C/E ratio
pH 7.2 (control)......................................................................11.3 6 0.8
pH 6 .........................................................................................16.5 6 0.4b
pH 8 .........................................................................................10.3 6 1.0
Viable cells, 48C......................................................................62.0 6 14.0b
Dead cells, 378C......................................................................14.46 4.3
Sodium fluoride ......................................................................11.1 6 1.7
Sodium cyanide....................................................................... 9.3 6 1.8
Carbonyl cyanide m-chlorophenyldrazone .......................... 9.76 1.7
2,4-Dinitrophenol ...................................................................13.4 6 3.5
a Experiments were carried out for 20 min at an extracellular concentration of
2 mg/ml with PMNs from five subjects.
b P , 0.05 compared with the control.
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active intracellularly in human PMNs. These properties, be-
sides its broad spectrum of activity, enhance the potential clin-
ical usefulness of this fluoroquinolone.
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